XASXCU6
Market cap845mUSD
Dec 23, Last price
4.22AUD
1D
0.00%
1Q
-51.10%
IPO
361.20%
Name
Clarity Pharmaceuticals Ltd
Chart & Performance
P/E
—
P/S
117.66
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
1.23%
Rev. gr., 5y
34.20%
Revenues
12m
+17.41%
Net income
-42m
L+72.03%
CFO
-43m
L+57.23%
Profile
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company has collaboration with GU Research Network for an investigator initiated Trial X-Calibur, using 64Cu-SAR-bisPSMA in known or suspected prostate cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.
IPO date
Aug 25, 2021
Employees
41
Domiciled in
AU
Incorporated in
AU
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | |
| Income | |||||||
Revenues | 11,507 17.41% | 9,801 51.74% | 6,459 102.06% | ||||
Cost of revenue | 56,307 | 36,164 | 28,015 | ||||
Unusual Expense (Income) | |||||||
NOPBT | (44,801) | (26,364) | (21,556) | ||||
NOPBT Margin | |||||||
Operating Taxes | 295 | (9,697) | 18 | ||||
Tax Rate | |||||||
NOPAT | (45,096) | (16,666) | (21,573) | ||||
Net income | (42,324) 72.03% | (24,602) 3.57% | (23,755) 132.40% | ||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 115,193 | 171 | 86,796 | ||||
BB yield | -7.78% | -0.09% | |||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | 243 | 179 | 79 | ||||
Net debt | (136,519) | (65,027) | (92,348) | ||||
| Cash flow | |||||||
Cash from operating activities | (43,237) | (27,500) | (13,314) | ||||
CAPEX | (504) | (47) | (213) | ||||
Cash from investing activities | (55,308) | 3,151 | (26,714) | ||||
Cash from financing activities | 115,213 | 232 | 86,928 | ||||
FCF | (51,004) | (20,733) | (20,422) | ||||
| Balance | |||||||
Cash | 136,506 | 65,015 | 92,336 | ||||
Long term investments | 13 | 12 | 12 | ||||
Excess cash | 135,943 | 64,537 | 92,025 | ||||
Stockholders' equity | 146,297 | 69,176 | 92,237 | ||||
Invested Capital | 10,597 | 4,817 | 291 | ||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | 273,158 | 260,410 | 248,465 | ||||
Price | 5.42 674.29% | 0.70 | |||||
Market cap | 1,480,517 712.19% | 182,287 | |||||
EV | 1,343,999 | 117,260 | |||||
EBITDA | (44,801) | (26,263) | (21,509) | ||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||